[Clinical effect and safety of XXXX 1200 mg in treating @entity363 ].

@entity1 @entity363 @entity5897
OBJECTIVE: To investigate the clinical effect and safety of @entity5897 1200 mg in treating @entity363 ( @entity363 ). METHODS: An open, multicentre, non case control clinical trial was conducted in 568 @entity1 suffering from @entity363 from Jul 1, 2006 to Nov 30, 2006. Routine examination, score of clinical symptoms and physical signs, mycetology test and safety evaluation were done in all @entity1 before treatment, 7 - 14 days after treatment and 30 days after treatment. RESULTS: Seven to fourteen days after treatment, 563 @entity1 could be followed and 323 @entity1 (57.3%) were cured. The overall effective rate was 90.2%. The mycologic cure rate was 91.3% (514). Thirty days after treatment, 480 @entity1 could be followed and 411 @entity1 (85.6%) were cured. The total effective rate was 96.0%. Mycologic cure rate was 92.3% (443/480). Adverse effect rate was 2.7% (15/563) and they were relieved without any treatment in one or two days. CONCLUSIONS: @entity5897 1200 mg is effective in the treatment of @entity363 , with good compliance and few adverse effects. Moreover, it can be accepted easily.
